February 28, 2018 / 12:16 AM / 9 months ago

BRIEF-Antisense Therapeutics Says ‍Approval Received For Phase Ii Trial Of Atl1102 In Duchenne Muscular Dystrophy​

Feb 28 (Reuters) - Antisense Therapeutics Ltd:

* ‍APPROVAL RECEIVED FOR PHASE II TRIAL OF ATL1102 IN DUCHENNE MUSCULAR DYSTROPHY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below